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Background: It is unclear whether the addition of dipeptidyl peptidase-4 inhibitors (DPP4-I) to statins may cause
coronary plaque regression in type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD).
Methods and results: Seventy-ﬁve T2DM patients with CAD who underwent percutaneous coronary intervention
under intravascular ultrasound (IVUS) guidance were randomized to receive DPP4-I sitagliptin (sitagliptin
group) or not to receive DPP4-I (non-DPP4-I group) as an add-on treatment to statins, and were followed-up
for 8–12months. Patientswith analyzable IVUS examinations of the non-culprit segmentwere included in the pri-
mary analysis. Sitagliptin group (n= 28) and non-DPP4-I group (n= 24) had signiﬁcant (p b 0.05) and similar
reduction in low-density lipoprotein cholesterol levels (−12 ± 24 and−12 ± 23mg/dL), and had no signiﬁcant
changes in hemoglobin A1c levels. Nominal change in percent atheroma volume (PAV), the primary endpoint, was
not signiﬁcant in both the sitagliptin and non-DPP4-I groups [mean (95% CI): +1.1% (−0.5 to 2.7%) and 0.2%
(−1.5 to 1.9%)]. The difference in change in PAV between sitagliptin and non-DPP4-I groups was also not signiﬁ-
cant [0.89% (−1.46%–3.25%)].
Conclusions: The addition of sitagliptin to statins did not cause coronary plaque regression in T2DMwith CAD.
© 2017 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a potent risk factor for athero-
sclerotic cardiovascular disease (ASCVD) [1,2], and among patients
with ASCVD, T2DM is signiﬁcantly associated with a worse prognosis
[3,4]. In addition, glycemic control has not been adequately demon-
strated to have a favorable effect on ASCVD in patients with T2DM
[5–7]. Moreover, there is no sufﬁcient evidence to help guide the
choice of class of glucose-lowering medications for reducing cardio-
vascular events in T2DM [8]. Treatment with statins is a standard
therapy for the secondary prevention of ASCVD [9,10], however,
they do not completely prevent cardiovascular events and residual
risk is still present, especially in T2DM patients with coronary artery
disease (CAD).
Dipeptidyl peptidase-4 inhibitors (DPP4-I) are a new class of
oral hypoglycemic agents for the treatment of T2DM that do not
cause weight gain [11]. DPP4-I promote postprandial insulin secre-
tion and suppress glucagon release by inhibiting the degradation of
incretin hormones such as glucagon-like peptide 1, glucose-
dependent insulinotropic peptide and other peptides [12]. Recent
evidence in animals and humans suggests that DPP4-I may also
have anti-atherosclerotic effects. DPP4-I, sitagliptin and alogliptin,
have been shown to inhibit the progression of atherosclerosis in
apolipoprotein E-deﬁcient mice [13–15]. In patients with T2DM,
sitagliptin and alogliptin are shown to improve endothelial func-
tion, have anti-inﬂammatory effects, and prevent the progression
of carotid atherosclerosis in T2DM patients [16–20]. Therefore,
DPP4-I may be useful for the prevention of CAD in T2DM patients.
However, it is still unclear whether DPP4-I may cause coronary
plaque regression in T2DM patients with CAD as an add-on to statin
therapy. The TOP-SCORE (assessment in patients with Type 2 diabe-
tes mellitus in addition to cOronary artery disease after Percutane-
ous coronary intervention with regard to Sitagliptin-induced
COronary plaque REgression) study was planned to evaluate the ef-
fect of the DPP4-I sitagliptin on coronary plaque as assessed by in-
travascular ultrasound (IVUS) when added to statins in T2DM
patients with CAD.
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2. Methods
2.1. Patients and study design
TOP-SCORE was a prospective, open, parallel, randomized, compara-
tive, single-center study to examine the effect of sitagliptin on coronary
plaque regression as assessed by IVUS in T2DM patients with CAD.
The study was performed according to the Declaration of Helsinki
regarding investigations in humans and approved by the ethics commit-
tee of Fukuoka University Hospital (EC/IRB: 11-3-03). Written informed
consentwas obtained fromeach patient. The present study has been reg-
istered with the University Hospital Medical Information Network
(UMIN000017861).
Eighty-ﬁve T2DM patients 30 years of age or older with CAD who
needed percutaneous coronary intervention (PCI) were screened from
December 2011 to July 2015 (Fig. 1A). The patients were eligible for
enrollment, if the hemoglobin A1c (HbA1c) level was 6.2% to 9.9% in
patients who were taking any hypoglycemic agents or 6.5% to 9.9%
in patients who were not receiving medical treatment for T2DM.
The exclusion criteria were as follows: (1) type 1 diabetes mellitus;
(2) patients who had experienced ketosis, diabetic coma and/or pre-
comawithin sixmonths prior to providing consent; (3)moderate to se-
vere heart failure [New York Heart Association class ≥ III, left ventricular
ejection fraction (LVEF) b40%]; (4) severe valvular heart disease;
(5) renal dysfunction (creatinine blood level of over 1.5 mg/dL in men
and over 1.3 mg/dL in women); (6) familial hypercholesterolemia;
(7) contraindication to antiplatelet agent; (8) history of chemical sensi-
tivity to DPP4-I; (9) pregnancy or lactation; and (10) severe infection,
trauma or recent surgery.
Seventy-ﬁve patients were enrolled and successfully underwent
PCI under IVUS guidance (Fig. 1A). Ten patients were not enrolled
for no informed consent (n= 7) or not suitable for the randomization
(n= 3).
All of the patients enrolled received a standard antiplatelet and statin
treatment, and systolic blood pressure (SBP) anddiastolic blood pressure
(DBP) were appropriately controlled, according to the Japanese Guide-
lines for Secondary Prevention of Myocardial Infarction [10]. Treatment
for dyslipidemia was based on the Japan Atherosclerosis Society Guide-
line for the Diagnosis and Prevention of Atherosclerotic Cardiovascular
Diseases (2007 or 2012 version) [21,22], and the target level of low-
density lipoprotein cholesterol (LDL-C) was b100 mg/dL.
The enrolled patients were randomly assigned to receive sitagliptin
at a standard dose of 50mg/day (n=38, sitagliptin group) or not to re-
ceive DPP4-I (n=37, non-DPP4-I group) (Fig. 1A). Randomization was
stratiﬁed by age (≥60 y or b60 y) and LDL-C level (≥100 mg/dL or
b100mg/dL). To achieve a target HbA1c level of b7.0%, the protocol per-
mitted up-titration of sitagliptin to 100 mg/day or addition of other hy-
poglycemic agent in the sitagliptin group, and addition of hypoglycemic
agents except for DPP4-I in the non-DPP4-I group. Hypoglycemic agents
were reduced if hypoglycemic symptoms were observed. The safety of
the patients was assessed by medical examination and blood tests at
3, 6, and 8 to 12 months of the study period.
Ultimately, a total of 52 patients who had analyzable IVUS examina-
tions at both baseline and follow-up were included in the primary anal-
ysis (Fig. 1A). Twenty-three patients were not included in the data
analysis for the following reasons: (1) withdrew informed consent (4
patients); (2) follow-up IVUS examination not performed (16 patients);
and (3) IVUS image not analyzable (3 patients) (Fig. 1A).
2.2. IVUS procedure and analysis
After IVUS-guided PCI of the culprit segment of coronary artery, IVUS
examination was conducted using an imaging catheter and a console
(View IT and VISIWAVE, Terumo, Tokyo, Japan). The patients received
an intracoronary injection of 1.0 to 2.0 mg of nitroglycerin just before
IVUS examination to prevent coronary spasm. The target segment for
IVUS analysis was selected at a non-PCI site (N5 mm proximal or distal
to the PCI site) on the PCI vessel. For reliable comparisons between base-
line and follow-up, a stent edge or an easily deﬁnable side branch was
used as a reproducible index (Fig. 1B and C). The IVUS catheter was ad-
vanced to the distal side of the PCI site and pulled back automatically
at a speed of 0.5mm/s. A total of 10 IVUS frameswere extracted at an in-
terval of 1.0 mm for a total length of 10 mm at the selected segment
using a motorized pullback system.
After a review of the IVUS images and selection of the target segment
(Fig. 1B and C), IVUS analysis was conducted by two experienced physi-
cians (A.I., observer 1; Y.K., observer 2) who were blinded to the patient
characteristics and group allocation according to the criteria described in
the American College of Cardiology Clinical Expert Consensus document
on IVUS [23].
The IVUS analysiswas carried out using a newquantitative IVUS anal-
ysis system (VISIATLAS, Terumo, Tokyo, Japan), which measures both
plaque volume and tissue characteristics of plaque. This new three-
dimensional (3-D) IVUS analysis system is comparable with the com-
monly used IVUS analysis system (echoPlaque™, INDEC Systems, Santa
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Fig. 1. (A) Flow chart of the study. Seventy-ﬁve T2DM patients with CAD who underwent
IVUS-guided PCI were randomized to receive sitagliptin (sitagliptin group) or not to
receive DPP4-I (non-DPP4-I group). Ultimately, 52 patients who had analyzable IVUS
examinations of a non-culprit lesion at baseline and at 8–12 months of follow-up were
included in the primary analyses. (B) Representative coronary angiogram of the evaluated
vessel for IVUS analysis. The analyzable segment is proximal to the stent deployed in the
RCA. (C) The proximal edge of the stent and the side branch were used as a reproducible
index for IVUS analysis at baseline and follow-up. The segment for the measurement of
IVUS needed to be N5 mm proximal to the PCI site, and the total length of the segment
was 10 mm. T2DM, type 2 diabetes mellitus; CAD, coronary heart disease; IVUS,
intravascular ultrasound; PCI, percutaneous coronary intervention; DPP4-I, dipeptidyl
peptidase-4 inhibitors; RCA, right coronary artery.
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Clara, CA, USA), and the reliability and validity have been demonstrated
previously [24].
For quantitative IVUS analysis, external elastic membrane (EEM)
cross-sectional area (CSA) and lumen CSA were manually traced in
each cross-section, and atheroma CSA (EEM CSA minus lumen CSA)
was automatically calculated (Fig. 2). Vessel volume and lumen volume
were automatically calculated as Σ EEM CSA and Σ lumen CSA,
respectively.
Total atheroma volume (TAV) and percent atheroma volume (PAV)
were calculated as follows:
TAV ¼ Σ EEM CSA–lumen CSAð Þ
PAV ¼ 100$ Σ EEM CSA–lumen CSAð Þ=Σ EEM CSA
The tissue characterization of plaque was analyzed using the soft-
ware of integrated backscatter IVUS (IB IVUS) attached to the above-
mentioned 3-D IVUS analysis system (Fig. 2). The plaque components
were classiﬁed into 4 categories: lipid, ﬁbrosis, dense ﬁbrosis, and calci-
ﬁcation by combining spectral parameters of posterior-scattering sig-
nals of IVUS [25]. The area and volume of each plaque component
were automatically calculated, and expressed as percentage.
2.3. Primary and secondary endpoints
Theprimary endpointwas thenominal change in PAVat the selected
segment from baseline to follow-up.
The secondary endpoint was the percent change in TAV at the select-
ed segment from baseline to follow-up, whichwas calculated as follows:
Percent change in TAV
¼ TAV at follow‐up‐TAV at baselineð Þ=TAV at baseline$ 100
Other secondary endpoints included the nominal changes in the
percent volumes of lipid, ﬁbrosis, dense ﬁbrosis, and calciﬁcation, and
changes in clinical laboratory data during the study period.
2.4. Clinical laboratory examinations
Fasting blood sugar (FBS) level, HbA1c level, serum levels of triglycer-
ide (TG), high-density lipoprotein cholesterol (HDL-C), and LDL-C, serum
creatinine level, high-sensitivity C-reactive protein (hs-CRP) level, and
uric acid (UA) level were measured at screening, at randomization, and
during the study period at the Fukuoka University Hospital Laboratory
Unit. Estimated glomerular ﬁltration rate (eGFR) was calculated as fol-
lows: 194 × serum creatinine−1.094 × age−0.287 (male), 194 × serum
creatinine−1.094 × age−0.287 × 0.739 (female).
2.5. Statistical data analysis
Statistical data analyses were performed using the SAS software
package (version 9.4, SAS Institute) at Fukuoka University (Fukuoka,
Japan). Frequency distributions of categorical variables including
gender, risk factors of CAD, and medications at baseline were compared
between groups by the chi-square test and/or Fisher's exact test. Con-
tinuous variables including clinical laboratory data and IVUS parameters
at baseline and follow-up were compared between groups using the
Wilcoxon rank-sum test. Non-parametric methods were used due to
the relatively small sample size [26]. Changes in continuous variables
during the study period for each group were examined by theWilcoxon
signed-rank test, and differences in the changes between groups were
examined by the Wilcoxon rank-sum test. The relations between two
continuous variables were examined by the Spearman rank correlation.
Equal variances of changes in PAV between groups were assessed by
the Ansari-Bradley test [27].
For quantitative IVUS analyses at baseline and follow-up, inter-
observer agreement of gray-scale IVUS parameters (vessel volume,
lumen volume, TAV, and PAV)was assessedwith the concordance corre-
lation coefﬁcient (CCC) [28] and Bland Altman analysis [29,30]. CCC was
estimated using U-statistic method, which is recommended for small
samples [28]. CCC and 95% conﬁdence interval (CI) were computed
using the SAS macro of Carrasco et al. [28]. For Bland Altman analysis,
the absolute difference and mean value were calculated for each pair of
measurement by the two observers and the percent difference between
the observers was calculated as absolute difference divided by themean
of two observers. Bland Altman plot was presented as scatter plot of the
absolute difference (y axis) verse themean value (x axis) of the two ob-
servers. Normality of the distribution of the absolute differences between
two observers was assessed by Shapiro-Wilk test, and the 95% limits of
agreement (LOA)were calculated asmean differences±1.96× standard
deviation (SD) of the differences between the two observers [29,30].
Mean and 95% CI for changes in PAV and percent change in TAV in
Sitagliptin and Non-DPP4-I groups were estimated by an analysis of var-
iance (ANOVA), and least-square (LS) mean (95% CI) was estimated by
Baseline Follow-up
Baseline Follow-up
IVUS
IB IVUS
IVUS
IB IVUS
lipid pool
fibrosis
dense fibrosis
calcification
B
A
*
*
*
*
*
Fig. 2. Representative conventional IVUS and IB IVUS images of the cross sections at
baseline and follow-up. (A) sitagliptin group. (B) non-DPP4-I group. The green and
yellow lines indicate the edges of the lumen and the external elastic membrane. The
red and white arrows indicate the guide wire and the artifact due to the guide wire,
respectively. * indicates side branches used as reproducible indices. PB, plaque burden;
IVUS, intravascular ultrasound; IB, integrated backscatter; DPP4-I, dipeptidyl peptidase-4
inhibitors. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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an analysis of covariance (ANCOVA) adjusting for baseline variables. The
standardized mean difference (Cohen's d-statistic) [31] in changes in
PAV during the study period between Sitagliptin andNon-DPP4-I groups
was used as themeasure of effect size for power analysis. The 95% CI for a
two sample Cohen's d was computed using the noncentrality parameter
CI [32]. Power analysis based on population effect size and sample effect
size were performed using noncentral F distribution [33,34]. Power
curve, showing changes in power (y axis) with sample size (x axis) for
different standardized effect size [35], was prepared using the Graph
Template Language (GTL) in SAS [36,37].
Data for continuous variables are presented as mean ± SD, median
[interquartile range (IQR, 25th to 75th percentile)], or mean (95% CI).
A P value of b0.05 was considered to be statistically signiﬁcant unless
indicated otherwise.
3. Results
3.1. Characteristics of T2DM patients with CAD and clinical laboratory data
Fig. 1 shows the ﬂow chart of the study. Fifty-two T2DM patients
with CAD who had complete end point assessment (analyzable IVUS
image at both baseline and follow-up) were included in the primary
analysis, based on intention-to-treat (ITT) principal. Four patients who
were randomized but had HbA1c levels slightly higher or lower than
the inclusion criteria were not excluded, because they received no addi-
tional treatment with insulin during the study period. Table 1 and Sup-
plementary Table I show the characteristics of T2DM patients with CAD
and clinical laboratory data in sitagliptin group (n = 28) and non-
DPP4-I group (n= 24). As shown in Table 1, age, gender, risk factors of
CAD, and history of CADwere not signiﬁcantly different between groups
at baseline. All of the T2DMpatientswith CADhad 1, 2, or 3 diseased ves-
sels andwere implanted with drug-eluting stent (DES) except that 3 pa-
tients in sitagliptin group were implanted with bare-metal stent (BMS)
(Table 1). The average follow-up period for sitagliptin group and non-
DPP4-I group was 8.9 ± 1.6 months and 8.5 ± 1.5 months, respectively.
Most of the T2DM patients with CAD in sitagliptin group (n = 21,
75%) and non-DPP4-I group (n = 20, 83%) were already receiving
statins at screening, and all of the patients were treated with statin at
randomization. However, two patients in the sitagliptin group stopped
statins for side effects after randomization (Table 1). SerumLDL-C levels
in sitagliptin group and non-DPP4-I group were already low at baseline
(95± 33mg/dL and 87± 26mg/dL, respectively), andwere further re-
duced at follow-up (83 ± 21 mg/dL and 73 ± 25 mg/dL, respectively)
(Supplementary Table I).
At baseline and at follow-up, sitagliptin group and non-DPP4-I group
were not signiﬁcantly different in serum levels of LDL-C, HDL-C, TG,
hsCRP, eGFR, and UA (Supplementary Table I).
At screening, 57% (n = 16) of the T2DM patients with CAD in
sitagliptin group were receiving DPP4-I (Table 1). At randomization, all
of the patients in sitagliptin group were treated with sitagliptin at
a standard dose of 50 mg/day, and concomitant administration of non-
DPP4-I hypoglycemic agentswere allowed (Table 1), for achieving target
level of glycemic control (HbA1c b 7%). The dose of sitagliptin was re-
duced to 25mg/day in one patient due to improved glycemic control, in-
creased to 100 mg/day in two patients, and discontinued in one patient
at the physician's discretion. Patients in non-DPP4-I group who were re-
ceiving DPP4-I at screening (n=11, 46%) were switched to non-DPP4-I
hypoglycemic agents for glycemic control at randomization (Table 1).
Therefore, non-DPP4-I group had a higher proportion of patients who
had insulin use (46% vs 11%, P = 0.006) and who received α-GI (42%
vs 18%, P= 0.07) at baseline as compared to sitagliptin group (Table 1).
HbA1c levels in T2DMpatientswith CAD in sitagliptin group and non-
DPP4-I group were 7.2 ± 1.0% and 7.3 ± 1.2%, respectively, at baseline,
and were maintained during the study period (Supplementary Table I).
Although HbA1c levels did not change signiﬁcantly from baseline to
follow-up in both sitagliptin group and non-DPP4-I group (0.0 ± 0.7%
and 0.2 ± 1.0%, respectively), there was a signiﬁcant increase in FBS
during the study period in both groups (Supplementary Table I).
Patients who were receiving anti-hypertensive drugs at screening
continued the medication throughout the study period (Table 1).
3.2. Conventional gray-scale IVUS and IB IVUS parameters for coronary
plaque
At baseline and follow-up, the volume and composition of coronary
plaque were analyzed in the selected segment of coronary artery using
conventional gray-scale IVUS and IB IVUS, respectively (Fig. 1B and C).
Representative IVUS images of the same cross sections at baseline and
follow-up for patients in sitagliptin group and non-DPP4-I group were
shown in Fig. 2. Table 2 shows the volume of coronary plaque as
Table 1
Baseline characteristics of T2DM patients with CAD in sitagliptin and non-DPP4-I groups.
Sitagliptin
(n= 28)
Non-DPP4-I
(n= 24)
P value
Age, y 70 ± 9 72 ± 10 0.47
Gender, Male (%) 22 (79%) 20 (83%) 0.74
BMI, Kg/m2 24.8 ± 4.1 25.1 ± 4.1 0.85
Smoking, n (%) 4 (14%) 3 (13%) 1.0
Hypertension, n (%) 22 (79%) 19 (79%) 1.0
Dyslipidemia, n (%) 24 (86%) 21 (88%) 1.0
Hyperuricemia, n (%) 7 (25%) 7 (29%) 0.74
Prior MI, n (%) 3 (11%) 3 (13%) 1.0
Prior PCI, n (%) 8 (29%) 7 (29%) 0.96
Prior CABG, n (%) 2 (7%) 1 (4%) 1.0
Type of CAD, n
SCAD/NSTE-ACS/STEMI 23/2/3 22/0/2 0.67
Number of diseased vessel, n
1/2/3 9/14/5 12/9/3 0.49
Target vessel, n
LAD/LCx/RCA/LMT 13/5/10/0 10/5/8/1 0.90
Stent, n
DES/BMS 25/3 24/0 0.24
Follow-up period, month 8.9 ± 1.6 8.5 ± 1.5 0.39
Medication at screening, n (%)
DPP-4 inhibitor 16 (57%) 11 (46%) 0.42
Statin 21 (75%) 20 (83%) 0.52
Medication at baseline, n (%)
Sitagliptin 28 (100%) 0 (0%) –
Insulin 3 (11%) 11 (46%) 0.006
Biguaniade 8 (29%) 11 (46%) 0.20
Sulfonylurea 3 (11%) 3 (13%) 1.0
α-GI 5 (18%) 10 (42%) 0.07
Glinide 1 (4%) 1 (4%) 1.0
Thiazolidine 2 (7%) 3 (13%) 0.65
Statin 26 (93%) 24 (100%) 0.49
Ezetimibe 0 (0%) 1 (4%) 0.46
EPA 3 (11%) 4 (17%) 0.69
ARB 18 (64%) 16 (67%) 0.86
ACE-I 3 (11%) 3 (13%) 1.0
CCB 19 (68%) 17 (71%) 0.82
β-blocker 4 (14%) 8 (33%) 0.19
Diuretics 5 (18%) 1 (4%) 0.20
Aldosterone blocker 1 (4%) 1 (4%) 1.0
Long-acting nitrate 4 (14%) 1 (4%) 0.36
Nicorandil 4 (14%) 2 (8%) 0.67
Aspirin 28 (100%) 24 (100%) –
Thienopyridine 28 (100%) 24 (100%) –
OAC 2 (7%) 2 (8%) 1.0
Data are presented as mean ± SD for continuous variables or the number (percent) of
patients for category variables.
T2DM, type 2 diabetes mellitus; CAD, coronary artery disease; DPP4-I, dipeptidyl
peptidase-4 inhibitors; BMI, body mass index; MI, myocardial infarction; PCI, percutane-
ous coronary intervention; CABG, coronary artery bypass grafting; SCAD, stable coronary
artery disease; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; STEMI,
ST-segment elevation myocardial infarction; LAD, left anterior descending; LCx, left
circumﬂex; RCA, right coronary artery; LMT; left main trunk; DES, drug-eluting stent;
BMS, bare-metal stent; DPP-4, dipeptidyl peptidase-4; α-GI, α-glucosidase inhibitor;
EPA, eicosapentaenoic acid; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-
converting enzyme inhibitor; CCB, calcium channel blocker; OAC, oral anticoagulants.
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measured by conventional IVUS analysis (upper panel) and the compo-
sition of coronary plaque as measured by IB IVUS (lower panel).
As shown in the upper panel of Table 2, at baseline, PAV in T2DMpa-
tients with CAD in sitagliptin group and non-DPP4-I group was 50.2 ±
9.3% and 49.2±11.8%, respectively, and the differences in PAV, TAV, ves-
sel volume, and lumen volume were not signiﬁcantly different between
groups. At follow-up, PAV in T2DM patients with CAD in sitagliptin
group and non-DPP4-I group was 51.3% ± 9.8% and 49.4% ± 11.9%,
respectively, and PAV, TAV, and vessel volume in each group were not
signiﬁcantly different from the baseline values (Table 2). Lumen volume
at follow-up was also not signiﬁcantly different between sitagliptin and
non-DPP4-I groups, but signiﬁcantly reduced in sitagliptin group as
compared to baseline (Table 2).
The nominal changes in PAV from baseline, the primary end point,
were not signiﬁcant in both sitagliptin group andnon-DPP4-I group [me-
dian (IQR):+0.7% (−1.4% to 3.5%) and0.2% (−2.7% to 2.7%), respective-
ly] (Table 2). The mean and 95% CI of the nominal changes in PAV were
+1.10% (−0.50%–2.70%) for sitagliptin group and +0.20% (−1.52%–
1.93%) for non-DPP4-I group (Fig. 3A, left panel). The nominal changes
in PAV was not signiﬁcantly different between sitagliptin and non-
DPP4-I groups (Table 2), as indicated by the largely overlaid 95% CIs of
nominal changes in PAV (Fig. 3A, left panel).
Percent changes in TAV, the secondary end point, were also not sig-
niﬁcant in T2DMpatients with CAD in sitagliptin group and non-DPP4-I
group (Table 2). The difference in percent changes in TAV between
sitagliptin and non-DPP4-I groups were also not signiﬁcant (Table 2),
as indicated by the 95% CI range of percent changes in TAV in the two
groups, i.e., 95% CI for sitagliptin group was included in that for non-
DPP4-I group (Fig. 3A, right panel).
As shown in the lower panel of Table 2, coronary plaque in both
T2DM patients with CAD in sitagliptin group and non-DPP4-I group
had a high percentage of lipid volume at baseline [median (IQR): 60.0%
(50.9%–64.9%) and 53.4% (38.7%–65.3%), respectively]. At follow-up, per-
cent lipid volume did not change signiﬁcantly frombaseline in sitagliptin
group, but signiﬁcantly reduced in non-DPP4-I group (Table 2). Howev-
er, the nominal changes in lipid volume were not signiﬁcantly different
between sitagliptin group and non-DPP4-I group (Table 2).
3.3. Relation of baseline LDL-C level and PAV with changes in PAV
The variation of changes in PAV was similar in sitagliptin group and
non-DPP4-I group, and the changes in PAV were not signiﬁcantly corre-
lated to baseline LDL-C levels, changes in LDL-C levels, and baseline PAV
in all of the patients (Supplementary Fig. I). After adjusting for baseline
LDL-C levels or baseline PAV, the change in PAVwas not signiﬁcantly dif-
ferent between sitagliptin group and non-DPP4-I group, as assessed by
an ANCOVA, and the LS mean for change in PAV (Supplementary Fig.
II) was very similar to the unadjusted mean change in PAV (Fig. 3) in
both sitagliptin group and non-DPP4-I group.
3.4. Inter-observer variability of IVUS measurement
The measurement errors for the gray-scale IVUS parameters,
i.e., vessel volume, lumen volume, TAV, and PAV, were small and similar
Table 2
Coronary plaque volume and composition as assessed by gray-scale IVUS and IB IVUS in T2DM patients with CAD in sitagliptin and non-DPP4-I groups at baseline and follow-up.
Sitagliptin (n= 28) P value (within group) Non-DPP4-I (n= 24) P value (within group) P value (between group)
IVUS parameters
Baseline
PAV, % 50.2 ± 9.3 49.2 ± 11.8 0.68
TAV, mm3 72.1 (61.0 to 98.4) 70.0 (57.2 to 90.0) 0.42
Vessel volume, mm3 150 (124 to 198) 142 (117 to 172) 0.39
Lumen volume, mm3 78.2 (58.2 to 95.4) 68.1 (46.9 to 94.2) 0.44
Follow up
PAV, % 51.3 ± 9.8 49.4 ± 11.9 0.48
TAV, mm3 71.8 (59.6 to 105) 72.6 (56.0 to 87.6) 0.51
Vessel volume, mm3 153 (119 to 198) 143 (114 to 171) 0.51
Lumen volume, mm3 71.1 (57.1 to 89.0) 65.0 (46.5 to 96.0) 0.69
Nominal change
PAV, % 0.7 (−1.4 to 3.5) 0.26 0.2 (−2.7 to 2.7) 0.85 0.49
Regression, n (%) 13 (46.4) 10 (41.7) 0.73
Progression, n (%) 15 (53.6) 14 (58.3)
TAV, mm3 −0.6 (−4.7 to 6.6) 0.89 1.3 (−1.9 to 5.0) 0.27 0.59
Vessel volume, mm3 −1.9 (−5.9 to 1.7) 0.07 0.5 (−2.8 to 2.2) 0.97 0.14
Lumen volume, mm3 −1.3 (−8.4 to 0.2) 0.016 0.2 (−3.7 to 3.0) 0.74 0.14
Pecent change, %
TAV, mm3 −1.3 (−5.4 to 8.7) 0.91 1.6 (−5.9 to 7.0) 0.60 0.73
Vessel volume, mm3 −1.4 (−3.1 to 0.9) 0.05 0.3 (−2.7 to 1.6) 0.85 0.27
Lumen volume, mm3 −2.5 (−12.2 to 0.4) 0.02 0.4 (−7.3 to 6.8) 0.98 0.13
IB IVUS parameters, %
Baseline
Lipid volume 60.0 (50.9 to 64.9) 53.4 (38.7 to 65.3) 0.28
Fibrous volume 34.1 (28.7 to 40.8) 41.4 (30.2 to 49.7) 0.13
Dense ﬁbrosis volume 3.4 (2.4 to 6.6) 4.1 (2.0 to 6.0) 0.56
Calciﬁed volume 0.8 (0.3 to 1.8) 1.1 (0.4 to 2.0) 0.82
Follow up
Lipid volume 55.6 (47.6 to 65.0) 50.7 (37.3 to 62.8) 0.28
Fibrous volume 37.1 (30.4 to 46.1) 41.9 (33.6 to 48.9) 0.26
Dense ﬁbrosis volume 4.1 (2.5 to 6.4) 4.8 (2.6 to 9.4) 0.55
Calciﬁed volume 1.2 (0.6 to 2.6) 1.3 (0.4 to 2.8) 0.96
Nominal change
Lipid volume −1.5 (−12.0 to 5.6) 0.26 −6.2 (−10.7 to−0.2) 0.014 0.48
Fibrous volume 0.8 (−3.3 to 9.9) 0.24 3.0 (−0.9 to 6.7) 0.029 0.68
Dense ﬁbrosis volume 0.3 (−0.2 to 0.7) 0.27 1.0 (−0.2 to 2.1) 0.016 0.39
Calciﬁed volume 0.1 (−0.2 to 0.7) 0.22 0.2 (0.0 to 1.3) 0.014 0.27
Data are presented as mean ± SD or median (interquartile range).
IB, integrated backscatter; IVUS, intravascular ultrasound; T2DM, type 2 diabetesmellitus; CAD, coronary artery disease; DPP4-I, dipeptidyl peptidase-4 inhibitors; PAV, percent atheroma
volume; TAV, total atheroma volume.
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in sitagliptin group and non-DPP4-I group at baseline and follow-up
(Supplementary Table II and Fig. 4). In all of the patients, the inter-
observer agreement was good for vessel volume, lumen volume, TAV,
and PAV measurements at baseline and follow-up, as indicated by CCC
(95% CI) [28] and limits of agreement of Bland Altman analyses [29]
(Supplementary Table II and Fig. 4). Sitagliptin group and non-DPP4-I
group were similar in the inter-observer variability for vessel volume,
lumen volume, TAV, and PAV measurement at baseline (Fig. 4a, c, e, g)
and follow-up (Fig. 4b, d, f, h), as shown by the Bland Altman plot,
which is the scatter plot of the differences between observer 1 and ob-
server 2 versus mean of two observers (Fig. 4). Therefore, the non-
signiﬁcant difference in changes in PAV between sitagliptin group and
non-DPP4-I group was not attributed to measurement error of IVUS
analysis.
3.5. Sample effect size and statistical power analysis
The mean difference in nominal changes in PAV between sitagliptin
group and non-DPP4-I groupwas 0.89% (95% CI:−1.46%–3.25%),which
was apparently not statistically signiﬁcant because the conﬁdence inter-
val included zero [32]. The statistical power (1-β) of the study, i.e., the
probability that under the alternative hypothesis (there is a true differ-
ences in changes in PAV between groups) the null hypothesis (there is
no differences in changes in PAV between groups) is rejected, was low
and estimated to be 12% based on sample effect size at the total sample
size of 52 and a two-side α of 0.05 (Fig. 3B, indicated by ﬁlled circle in
blue). Therefore, a non-signiﬁcant difference in changes in PAV between
sitagliptin group and non-DPP4-I group does not indicate that there is
nodifference in changes in PAV between group, but suggests that the ef-
fect size is small. The sample standardized effect size (Cohen's d) was
estimated to be 0.21, and zero was included in the 95% CI of Cohen's d
(−0.34%–0.75%).
Statistical power analysis based on population effect sizewas shown
in Fig. 3B. From the power curve, which is the plot of power (1-β) as a
function of sample size based on assumed standard effect size of 0.2,
0.4, and 0.8 at a two-side α of 0.05, a large effect size (0.8) would be
detected for a total sample size of 50 at 80% power (Fig. 3B).
In summary, in T2DM patients with CAD who were treated with
statins, addition of sitagliptin did not show additional effects in
regressing coronary plaque under condition of medication for optimal
glycemic control.
4. Discussion
The TOP-SCORE study examined the effects of sitagliptin on coronary
atherosclerosis in T2DM patients with CAD.We found that sitagliptin, as
an add-on therapy to statins, did not have an additional effect on the PAV
as assessed by IVUS in T2DMpatientswith CAD, under condition ofmed-
ication for optimal glycemic control.
T2DM is an important risk factor of CAD andCAD is themajor compli-
cation of T2DM that causes death. Therefore, cardiovascular safety of hy-
poglycemic agents is in concern, and severalmeta-analyses reported that
sitagliptin, linagliptin, and other DPP-4 inhibitors did not increase major
adverse cardiovascular events (MACE) [38–40]. Cardiovascular outcome
studies in T2DM patients who had, or at high risk for, cardiovascular dis-
ease consistently reported that sitagliptin, alogliptin, and saxagliptin did
not increase the risk of MACE as compared with placebo [41–43]. In the
present study, since the study subjects were high risk T2DM patients
who required PCI, the use of placebo was not possible. We added
sitagliptin to usual care and compared with non-DPP4-I hypoglycemic
agents (Fig. 1A). Our ﬁnding that adding sitagliptin to usual care did
not have an additional effect on coronary atherosclerosis as compared
with non-DPP4-I (Table 2, Fig. 3A) supports those of the cardiovascular
outcome studies [41–43].
Recently, DPP4-I is shown to have anti-atherogenic effects in addition
to anti-hyperglycemic effects. Animal studies using apoE-deﬁcient mice
showed that des-ﬂuoro-sitagliptin and alogliptin inhibit the progression
of aortic atherosclerosis [14,15]. More recent studies in patients with
T2DM free of apparent cardiovascular disease showed that sitagliptin
and alogliprin prevents the progression of carotid atherosclerosis [19,
20]. However, the effects of sitagliptin on coronary atherosclerosis in
T2DM patients with CAD are not clear.
We did not detect an effect of sitagliptin on the volume of coronary
plaque as assessed by gray-scale IVUS (Table 2, Fig. 3A) and lipid compo-
nent of coronary plaque as assessed by IB IVUS (Table 2). The PAV in our
T2DMpatients with CAD at baseline (Table 2) was similar to that report-
ed by other studies in Japanese patients with stable angina pectoris and
acute coronary syndrome (ACS) at baseline [44,45]. Themajor reason for
this ﬁnding is that about 80% of the T2DM patients in the present study
had already been receiving statins at screening due to the high risk for
CAD (Table 1). Early statin treatment with atorvastatin for 6 month has
been shown to reduce coronary plaque in ACS and the percent change
in plaque volume was positively correlated to the percent reduction in
LDL-C level [46]. Also, early intervention with rosuvastatin for
6months reduced lipid component of non-culprit plaque of coronary ar-
tery in ACS [47]. Therefore, ourﬁnding of a non-signiﬁcant change in PAV
in T2DM patients with CAD (Table 2, Fig. 3A) indicates that continued
statin treatment prevented the progression of coronary atherosclerosis,
under condition of medication with hypoglycemic agents for optimal
glycemic control (Supplementary Table I), since diabetes have been
shown to have accelerated progression of coronary atherosclerosis [48].
Sitagliptin
Non-DPP4-I
Mean (95% CI) Mean (95% CI)
A
B
Nominal change in 
PAV (%) Percent change in TAV (%)
Sample size
(52, 0.12)
Po
w
er
Effect size: 0.20
Effect size: 0.40
Effect size: 0.80
Fig. 3. (A) Mean (ﬁlled circle in blue) and 95% CI (bar in red) of nominal change in PAV
(left panel) and percent change in TAV (right panel) in T2DM patients with CAD in
sitagliptin group and non-DPP4-I group. (B) Power curve plotting power (1-β) as a
function of sample size based on assumed population standardized effect size of 0.2, 0.4,
and 0.8 at a two-side α of 0.05. Filled circle in blue indicates empirical power estimated
based on sample effect size and the total number of patients at at a two-side α of 0.05.
CI, conﬁdence interval; PAV, percent atheroma volume; TAV, total atheroma volume;
T2DM, type 2 diabetes mellitus; CAD, coronary heart disease; DPP4-I, dipeptidyl
peptidase-4 inhibitors. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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T2DM is associatedwith increased levels of atherogenicmodiﬁed LDL
including oxidized LDL and electronegative LDL [49]. Statins effectively
reducemodiﬁed LDL in short term (within 1month) [50–52]. Therefore,
for the same reason,we did not observe a signiﬁcant correlation between
the change in PAV and the reduction in LDL-C level in T2DM patients
with CAD (Supplementary Fig. Ib).
In the present study, neither signiﬁcant progression nor regression of
coronary plaque was observed in the 52 T2DM patients with CAD,
because 56% (n= 15 + 14) of the patients had increased PAV and 44%
(n = 13 + 10) of the patients had reduced PAV (Table 2). The change
in PAV was also not related to baseline LDL-C level and baseline PAV
(Supplementary Fig. Ia and Ic).
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Fig. 4. Scatter plots of thedifferences in vessel volume (a, b), lumenvolume (c, d), TAV (e, f), and PAV (g, h) between observer 1 andobserver 2 versusmeanof the two observers at baseline
(left panel) and follow-up (right panel). The red and green ﬁlled triangles indicate data in the sitagliptin group and the non-DPP4-I group, respectively. TAV, total atheroma volume; PAV,
percent atheroma volume; DPP4-I, dipeptidyl peptidase-4 inhibitors. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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We observed a favorable change toward stabilization of coronary
plaque, as indicated by a reduction in percent lipid volume and an
increase in percent ﬁbrosis volume, in non-DPP4-I group, although
not in sitagliptin group (Table 2). At follow-up, the non-DPP4-I group
tended to have lower TG level (Supplementary Table I), which may be
associated with lower level of atherogenic remnant lipoproteins [53]. It
is also possible that the class of hypoglycemic agents may be related to
the reduced lipid component of coronary plaque in non-DPP4-I group,
which, however, needs further investigation.
Our studyhas the limitation that about 50% of the patients had already
been taking DPP4-I before randomization (Table 1), and a wash-out peri-
od was not possible. Also, the sample size was small (52 patients were
included in the primary analyses) and the follow-up period was not
long enough (8–12 months). Therefore, it is possible that the anti-
atherogenic effect of sitagliptinwas not detected due to the lack of power.
However, we have make the greatest efforts to minimize the mea-
surement error of IVUS parameters, which was shown to be similar in
sitagliptin and non-DPP4-I groups at baseline and follow-up (Fig. 4).
Although a nonsigniﬁcant difference in PAV between sitagliptin and
non-DPP4-I groups (p = 0.49, Table 2) indicates low statistical power
and no conclusion can be made on the null hypothesis that there is no
difference in change in PAV between groups [34], the low power in our
study can indicate a small effect size (Fig. 3B, Supplementary Fig. II),
which is independent of sample size [54]. The mean differences in
change in PAV between sitagliptin and non-DPP4-I groups we observed
was 0.89%, and the 95% CI range (−1.46%–3.25%) included zero [32]. In
fact, a smaller study with T2DM who underwent elective PCI (n = 28)
[55] reported that changes in PAV in sitagliptin group (n=15) and con-
trol group (n=11)were 0.2%± 2.0% and 0.5%± 3.5%, respectively. This
study of Nozue et al. was a prospective, open-labeled, randomized, mul-
ticenter trial performed at 6 Japanese centers, and was published during
the revision of this manuscript [55]. Our study is similar to the study of
Nozue et al. [55] in that the background of patients was similar and the
change in PAV was used as the primary end point. The ﬁndings of the
two studies are also consistent.
In conclusion, sitagliptin did not cause coronary plaque regression
when added to statins in T2DM patients with CAD.
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Supplementary Table I. Clinical laboratory data in T2DM patients with CAD in sitagliptin and 
non-DPP4-I groups at baseline and follow-up 
Baseline
HbA1c,  (%) 7.2 ± 1.0 7.3 ± 1.2 0.96
FBS, mg/dL 114 ± 38 108 ± 28 0.47
LDL-C, mg/dL 95 ± 33 87 ± 26 0.49
HDL-C, mg/dL 47 ± 12 49 ± 14 0.54
TG, mg/dL 147 ± 53 131 ± 66 0.13
hsCRP, mg/dL 0.33 ± 0.93 0.61 ± 1.13 0.44
eGFR, mL/min/1.73m2 64 ± 15 61 ± 17 0.34
UA, mg/dL 5.6 ± 1.7 5.4 ± 1.6 0.83
SBP, mmHg 126 ± 13 131 ± 19 0.56
DBP, mmHg 69 ± 10 70 ± 13 0.69
LVEF,  (%) 65 ± 10 66 ± 10 0.67
Follow up
HbA1c,  (%) 7.2 ± 1.0 7.5 ± 1.5 0.64
FBS, mg/dL 124 ± 32 125 ± 37 0.96
LDL-C, mg/dL 83 ± 21 75 ± 25 0.23
HDL-C, mg/dL 49 ± 12 50 ± 15 0.81
TG, mg/dL 138 ± 59 114 ± 65 0.07
hsCRP, mg/dL 0.19 ± 0.29 0.11 ± 0.14 0.78
eGFR, mL/min/1.73m2 63 ± 18 58 ± 17 0.28
UA, mg/dL 5.5 ± 1.7 5.4 ± 1.5 1.0
SBP, mmHg 126 ± 15 127 ± 14 0.51
DBP, mmHg 69 ± 10 67 ± 11 0.38
LVEF,  (%) 65 ± 7 66 ± 8 0.57
Norminal change
HbA1c,  (%) 0.0 ± 0.7 0.97 0.2 ± 1.0 0.56 0.41
FBS, mg/dL 10 ± 27 0.048 16 ± 40 0.042 0.78
LDL-C, mg/dL -12 ± 24 0.027 -12 ± 23 0.016 0.54
HDL-C, mg/dL 1 ± 11 0.55 1 ± 7 0.50 0.95
TG, mg/dL -10 ± 64 0.34 -10 ± 49 0.17 0.76
hsCRP, mg/dL -0.15 ± 0.94 0.53 -0.50 ± 1.15 0.08 0.39
eGFR, mL/min/1.73m2 -1 ± 11 0.50 -3 ± 6 0.021 0.56
UA, mg/dL -0.1 ± 0.9 0.42 0.0 ± 1.8 0.65 0.41
SBP, mmHg 0 ± 18 0.96 -4 ± 20 0.40 0.68
DBP, mmHg 0 ± 11 0.89 -4 ± 13 0.18 0.22
LVEF,  (%) 1 ± 11 0.64 1 ± 9 0.99 0.71
Sitagliptin
P value
(within
group)
Non-DPP4-I
P value
(within
group)
P value
(between
group)(n=28) (n=24)
 
Data are presented as mean ± SD. 
T2DM, type 2 diabetes mellitus; CAD, coronary artery disease; DPP4-I, dipeptidyl peptidase-4 inhibitors; 
HbA1c, hemoglobin A1c; FBS, fasting blood sugar; LDL-C, low-density lipoprotein cholesterol; HDL-C, 
high-density lipoprotein cholesterol; TG, triglyceride; hs-CRP, high-sensitivity C-reactive protein; eGFR, 
estimated glomerular filtration rate; UA, uric acid; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; LVEF, left ventricular ejection fraction. 
Supplementary Table II. Inter-observer variability for gray-scale IVUS analyses in T2DM patients with CAD at baseline and follow-up 
Mean
difference
Mean
difference
(absolute) (%)
Baseline
Vessel volume, mm3 151.9 ± 51.2 152.4 ± 51.2 0.998 (0.997, 0.999) 0.44 0.24 ± 5.8 ± 5.3
Lumen volume, mm3 76.7 ± 32.5 76.4 ± 31.8 0.997 (0.994, 0.998) -0.28 -0.03 ± 5.2 ± 8.5
TAV, mm3 75.2 ± 28.3 76.0 ± 28.7 0.994 (0.992, 0.996) 0.72 0.47 ± 5.7 ± 10.8
PAV, % 49.7 ± 10.5 49.8 ± 10.5 0.984 (0.978, 0.989) 0.13 0.23 ± 3.6 ± 9.0
Follow up
Vessel volume, mm3 150.8 ± 50.8 150.8 ± 51.0 0.999 (0.998, 0.999) 0.02 -0.14 ± 5.1 ± 4.5
Lumen volume, mm3 74.7 ± 31.6 74.6 ± 31.8 0.997 (0.996, 0.998) -0.12 -0.16 ± 4.4 ± 6.8
TAV, mm3 76.1 ± 28.7 76.2 ± 29.2 0.997 (0.995, 0.998) 0.13 -0.49 ± 4.5 ± 10.6
PAV, % 50.5 ± 10.6 50.4 ± 11.0 0.988 (0.981, 0.992) -0.06 -0.36 ± 3.3 ± 7.9
Limits of
agreement
(%)
Bland Altman analysis
Limits of
agreement
(absolute)(Mean±SD) (Mean±SD)
Observer 1 Observer 2
Mean values Correlation
CCC (95% CI)
 
IVUS, intravascular ultrasound; T2DM, type 2 diabetes mellitus; CAD, coronary artery disease; DPP4-I, dipeptidyl peptidase-4 inhibitors; 
PAV, percent atheroma volume; TAV, total atheroma volume; CCC, concordance correlation coefficient.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure I. Scatter plots of the changes in PAV versus baseline LDL-C levels (a), changes 
in LDL-C levels (b), and baseline PAV (c). The red and green filled circles indicate data in the 
sitagliptin group and the non-DPP4-I group, respectively. PAV, percent atheroma volume; LDL-C, 
low-density lipoprotein cholesterol; DPP4-I, dipeptidyl peptidase-4 inhibitors. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure II. Least square (LS) mean (filled circle in blue) and 95% CI (bar in red) of 
nominal change in PAV (left panel) and percent change in TAV (right panel) in T2DM patients 
with CAD in sitagliptin group and non-DPP4-I group, adjusting for baseline LDL-C levels (A) or 
baseline PAV (B) by an analysis of covariance. CI, confidence interval; PAV, percent atheroma 
volume; TAV, total atheroma volume; T2DM, type 2 diabetes mellitus; CAD, coronary heart 
disease; DPP4-I, dipeptidyl peptidase-4 inhibitors. 
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